The product information that follows concerns a prescription-only medicine and is intended for registered healthcare professionals in Pakistan. Please confirm to continue.
Zoledronic acid for infusion — protecting bone in hypercalcaemia of malignancy, bone metastases, osteoporosis and Paget's disease.
Zolegen® is zoledronic acid for intravenous infusion, presented as 5 mg/100 mL and 4 mg/5 mL. It potently inhibits osteoclast activity, stopping excess calcium release from bone.
Inhibits osteoclast-mediated bone resorption.
Lowers the risk of skeletal complications in advanced cancer involving bone.
Single annual infusion in the approved osteoporosis indication.
Infusion over not less than 15 minutes.
Each indication applies to a specific strength. Refer to the approved prescribing information for the indication and dose of each presentation.
Zoledronic acid 5 mg in 100 mL, and 4 mg in 5 mL concentrate, for intravenous infusion.
Intravenous infusion over not less than 15 minutes. Ensure adequate hydration before each dose. The dose depends on the indication and presentation — see the approved prescribing information.
As stated on the carton. Do not use after the expiry date printed on the label.
See the important safety information below.
| Brand | Zolegen® |
|---|---|
| Generic | Zoledronic acid |
| Presentations | 5 mg/100 mL solution for infusion; 4 mg/5 mL concentrate |
| Dosage form | Solution / concentrate for intravenous infusion |
| Pack | Available on request |
| Therapeutic area | Oncology & bone health |
| Prescription status | Prescription-only medicine |
| Manufacturer | Available on request |
| DRAP registration no. | Available on request |
| Marketed by | Salventis Pharma SMC (Pvt.) Ltd., Islamabad |
